Fadini, G. P., Bonora, B. M., Zatti, G., Vitturi, N., Iori, E., Marescotti, M. C., . . . Avogaro, A. (2017). Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: A randomized placebo-controlled trial. Cardiovasc Diabetol.

Fadini, Gian Paolo, Benedetta Maria Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Cristina Marescotti, Mattia Albiero, and Angelo Avogaro. "Effects of the SGLT2 Inhibitor Dapagliflozin On HDL Cholesterol, Particle Size, and Cholesterol Efflux Capacity in Patients With Type 2 Diabetes: A Randomized Placebo-controlled Trial." Cardiovasc Diabetol 2017.

Fadini, Gian Paolo, et al. "Effects of the SGLT2 Inhibitor Dapagliflozin On HDL Cholesterol, Particle Size, and Cholesterol Efflux Capacity in Patients With Type 2 Diabetes: A Randomized Placebo-controlled Trial." Cardiovasc Diabetol 2017.